Cyclo Therapeutics (CYTH) Q2 2024 earnings summary

Executive summary

• Cyclo Therapeutics is a clinical-stage biotech focused on cyclodextrin-based therapies for neurodegenerative diseases, with lead candidate Trappsol® Cyclo™ in Phase III for Niemann-Pick Type C (NPC) and Phase II for Alzheimer's disease.

• The company completed enrollment of 104 patients in its pivotal Phase III NPC trial in May 2024 and received a European patent for Alzheimer's treatment methods in July 2024.

• Legacy fine chemical business continues, but the core focus has shifted to biopharmaceutical development.

Financial highlights

• Net loss was $5.98 million for Q2 2024 and $10.32 million for the six months ended June 30, 2024, compared to $4.64 million and $9.64 million for the same periods in 2023.

• Revenue increased 5% year-over-year to $123,000 for Q2 2024 and 21% to $326,000 for the six months, driven by product mix changes.

• Cash and cash equivalents fell to $1.12 million as of June 30, 2024, from $9.25 million at December 31, 2023.

• Negative working capital of $5.38 million as of June 30, 2024, compared to positive $3.85 million at year-end 2023.

• Net cash used in operating activities was $10.03 million for the first half of 2024, up from $7.85 million in the prior year period.

Outlook and guidance

• Additional capital will be required to fund ongoing clinical trials, development, and commercialization efforts.

• Management is exploring equity, debt, asset sales, and non-dilutive funding, but substantial doubt exists about the company's ability to continue as a going concern.